Ozette
Ozette is a privately held biotechnology research company based in Seattle, WA, founded in 2021, focusing on unlocking the power of the immune system to treat and prevent disease through advanced computational biology techniques.
Company Overview
Ozette is a biotechnology research company founded in 2021. Headquartered in Seattle, WA, the company boasts a small but specialized team of 46 individuals. Ozette's mission is to unlock the power of the immune system to treat and prevent disease. The company is privately held and integrates advanced computational biology techniques to analyze immune system data.
Biotechnology Innovations
Ozette is at the forefront of biotechnology innovations, developing personalized medicine approaches to enhance treatment efficacy. The company's platform offers near real-time automated biomarker endpoint analysis for flow cytometry data. Leveraging machine learning algorithms such as FAUST, Ozette discovers and annotates cellular phenotypes. The company's 48-color full spectrum cytometry assay enables comprehensive immune profiling, and its use of CITE-Seq technology allows for simultaneous quantification of cell surface protein and RNA expression.
Collaborations and Partnerships
Ozette collaborates with leading academic institutions and partners with both pharmaceutical and academic organizations for research and clinical development. Notable partnerships include those with Bloodworks Northwest to leverage lab and immune cell population discovery platforms, and Umoja Biopharma to discover novel oncology insights. The company was seeded at Fred Hutch and incubated at AI2, with seed funding led by Madrona Ventures.
Technology and Platform
Ozette offers a cloud-native platform designed for interim analysis and quality assurance during ongoing studies. This platform features a user-friendly dashboard for interactive exploration of single-cell data. The company has developed a suite of machine learning-powered computational analysis solutions called Assay-to-Insights, and showcased its automated approach to high-parameter spectral flow cytometry assay validation at CYTO 2024.
Quality and Compliance
Ozette employs a robust Quality Management System that integrates quality principles into all business processes. The company complies with various regulatory guidelines including 21 CFR Parts 11, 50, 54, 56, 812, 820 (FDA) and ISO 13485:2016. Furthermore, Ozette follows industry best practices for information security, incorporating measures such as encryption and access controls.